Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress - Press Release
FLT180a generated protective FIX levels with no bleeding or need for FIX replacementThe treatment was well tolerated with a good safety profileLONDON,
Source: wiredprnews.com